Rejuvenate Bio

Rejuvenate Bio lands $4m grant to develop gene therapy with longevity potential California Institute for Regenerative Medicine (CIRM) funding will support the company through IND-enabling studies of FGF21-boosting gene therapy for genetic heart condition. #longevity #funding #genetherapy

Rejuvenate Bio secures $4M grant from California Institute for Regenerative Medicine (CIRM) to advance groundbreaking gene therapy for DSP ACM, targeting life-threatening heart conditions. CEO Daniel Oliver and CSO Noah Davidsohn highlight the transformative potential of RJB-0402 in reshaping treatment paradigms. #Biotech #GeneTherapy #HealthInnovationhttps: //https://lnkd.in/g73WkrwW

Excited to announce we received $4M in funding today from California Institute for Regenerative Medicine (CIRM) to advance IND-enabling activities for RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). “DSP ACM is a rare, severe, life-threatening, and debilitating disease that typically manifests in young adults as a high risk of life-threatening ventricular arrhythmias, sudden cardiac death, and progression to heart failure,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “There is currently no disease modifying therapy for patients with this disease, and our gene therapy RJB-0402 addresses a significant unmet medical need.” Read the press release: https://lnkd.in/eigtVhtm

Excited to announce we received $4M in funding today from California Institute for Regenerative Medicine (CIRM) to advance IND-enabling activities for RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). “DSP ACM is a rare, severe, life-threatening, and debilitating disease that typically manifests in young adults as a high risk of life-threatening ventricular arrhythmias, sudden cardiac death, and progression to heart failure,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “There is currently no disease modifying therapy for patients with this disease, and our gene therapy RJB-0402 addresses a significant unmet medical need.” Read the press release: https://lnkd.in/eigtVhtm

Sharing some photos from our panel at #BIO2024 on #Increasing #Healthspan, featuring our CEO & Co-Founder Daniel Oliver. 🧬🧬🧬 Great meeting everyone last week and looking forward to the next event!

𝐁𝐈𝐎 𝟐𝟎𝟐𝟒: Rejuvenate Bio CEO Daniel Oliver on the company's liver directed gene therapy program targeting FGF21. #BIO2024 He describes how Rejuvenate believes this program could have utility against arrhythmias and heart failure in both humans and dogs. Full video: https://lnkd.in/gHuvfdvD BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

We’re excited to see everyone next month at #BIO2024! Our CEO Daniel Oliver will be speaking on a panel on Monday, June 3. Join us for an this panel discussion as we delve into the fascinating realm of longevity and explore strategies for extending our healthspan. In this engaging session, our panel of experts will unravel the science and novel therapies in development that could contribute to a longer, healthier life. More info: https://lnkd.in/eiUbyfym

Our chief scientific officer and co-founder Noah Davidsohn will be presenting at the American Society of Gene & Cell Therapy 2024 meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. 🧬🧬 “We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio. “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options. If our approach proves effective to treat ACM, it would have a dramatic impact on the profound burden this disease has on patients and their families.” Title: AAV FGF21 Gene Therapy as a Variant Agnostic Treatment for Arrhythmogenic Cardiomyopathy Session Type: In-Person Oral Presentation Session Title: Next Generation Gene & Cell Therapies for Heart, Lung, and Kidney Diseases Abstract Number: 79 Location: Room 314-317 Session Date/Time: Wednesday May 8, 2024 1:30 PM - 3:15 PM Read the full release: 👇👇 https://lnkd.in/e9Qhtvws

Our next Larger than Life Science event is one week from today in #sandiego with Longfellow Real Estate Partners and Nucleate! Don't miss this lineup as we discuss the emerging field of anti-aging and the revolutionary technologies employed to both understand and address the aging process. Sign up here: https://lnkd.in/dCspB2Sf

Chronic diseases are the leading causes of death and disability in America, and they are also a leading driver of healthcare costs. In this episode, Dr. Noah Davidsohn, CSO and co-founder of Rejuvenate Bio, describes his company’s gene therapy approach to treating chronic age-related disease. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/gghfCYCg (click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka